^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    fludarabine IV

    i
    Other names: NSC 312887, NSC-312887, NSC312887
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    1d
    PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Beijing Biotech
    New P1/2 trial • Liquid biopsy
    |
    cyclophosphamide • fludarabine IV
    1d
    Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Beijing Biotech
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSLN (Mesothelin) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
    |
    HER-2 positive • HER-2 expression
    |
    cyclophosphamide • fludarabine IV
    1d
    Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer (clinicaltrials.gov)
    P1, N=210, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2033 --> Feb 2029 | Trial primary completion date: Jun 2031 --> Feb 2029
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • SLATE-KRAS
    4d
    Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum (clinicaltrials.gov)
    P1/2, N=10, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV • rimiducid (AP1903)
    4d
    Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    cyclophosphamide • fludarabine IV
    4d
    AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=45, Completed, Artiva Biotherapeutics, Inc. | Active, not recruiting --> Completed | Trial primary completion date: Aug 2024 --> Oct 2025
    Trial completion • Trial primary completion date
    |
    Rituxan (rituximab) • cyclophosphamide • bendamustine • fludarabine IV • AlloNK (GCC4001)
    5d
    Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Shenzhen University General Hospital
    New P1/2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    cyclophosphamide • fludarabine IV
    5d
    Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma (clinicaltrials.gov)
    P1, N=17, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion • First-in-human
    |
    BRAF (B-raf proto-oncogene) • IL2 (Interleukin 2)
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • TIDAL-01
    5d
    Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, Masonic Cancer Center, University of Minnesota | N=33 --> 3 | Trial primary completion date: Dec 2026 --> Mar 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    fludarabine IV
    5d
    Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=200, Recruiting, Chinese PLA General Hospital | Trial completion date: Jan 2026 --> Jan 2030 | Trial primary completion date: Jan 2026 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • fludarabine IV • aclarubicin
    6d
    TAK-012-1501: A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=16, Terminated, Takeda | Trial completion date: May 2026 --> Nov 2025 | Active, not recruiting --> Terminated; Sponsor decision (No safety concern)
    Trial completion date • Trial termination
    |
    cyclophosphamide • fludarabine IV • TAK-012
    7d
    Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC (clinicaltrials.gov)
    P1, N=20, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Recruiting | N=13 --> 20 | Trial primary completion date: Dec 2025 --> Jun 2026
    Enrollment open • Enrollment change • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • cyclophosphamide • fludarabine IV